Boehringer To Pay $13.5M To End Off-Label Marketing Claims
Drugmaker Boehringer Ingelheim Pharmaceuticals Inc. has agreed to distribute $13.5 million among all 50 states and the District of Columbia to end allegations that it marketed four of its prescription drugs...To view the full article, register now.
Already a subscriber? Click here to view full article